Rubius Therapeutics CEO Pablo Cagnoni's 2021 pay jumps 45% to $5M
Rubius Therapeutics reports 2021 executive compensation
By ExecPay News
Published: March 30, 2022
Rubius Therapeutics reported fiscal year 2021 executive compensation information on March 30, 2022.
In 2021, five executives at Rubius Therapeutics received on average a compensation package of $2.7M, a 20% increase compared to previous year.
Average pay of disclosed executives at Rubius Therapeutics
Pablo J. Cagnoni, Chief Executive Officer, received $5M in total, which increased by 45% compared to 2020. 60% of Cagnoni's compensation, or $3M, was in option awards. Cagnoni also received $363K in non-equity incentive plan, $598K in salary, $1M in stock awards, as well as $11K in other compensation.
Dannielle Appelhans, Chief Operating Officer, received a compensation package of $3.7M. 59% of the compensation package, or $2.2M, was in option awards.
Maiken Keson-Brookes, Chief Legal Officer, earned $2.1M in 2021, a 249% increase compared to previous year.
Laurence Turka, Chief Scientific Officer, received $2M in 2021, which decreases by 16% compared to 2020.
Jose Carmona, Chief Financial Officer, earned $659K in 2021.
Related executives
You may also like
Source: SEC filing on March 30, 2022.